Study | Trial name | Year | Tumor type | Intervention | Control | Median PFS (mo) | HR (95% CI) |
Rinke et al. (58) | PROMID | 2009 | Midgut | Octreotide LAR (30 mg/4 wk) | Placebo | 14 vs. 6 | 0.34 (0.20–0.59) |
Caplin et al. (59) | CLARINET | 2014 | Pancreatic, midgut, hindgut | Lanreotide (120 mg/4 wk) | Placebo | NR at 24 vs. 18 | 0.47 (0.30–0.73) |
Pavel et al. (60) | RADIANT-2 | 2011 | NET + carcinoid syndrome | Everolimus (10 mg/d)* | Placebo* | 16 vs. 11 | 0.77 (0.59–1.00) |
Yao et al. (61) | RADIANT-3 | 2011 | Pancreatic | Everolimus (10 mg/d)* | Placebo* | 11 vs. 5 | 0.35 (0.27–0.45) |
Yao et al. (62) | RADIANT-4 | 2016 | Nonfunctioning lung/gastrointestinal tract | Everolimus (10 mg/d)* | Placebo* | 11 vs. 4 | 0.48 (0.35–0.67) |
Raymond et al. (63) | 2011 | Pancreatic | Sunitinib (37.5 mg/d)* | Placebo* | 11 vs. 6 | 0.42 (0.26–0.66) | |
Strosberg et al. (45) | NETTER-1 | 2017 | Midgut | [177Lu-DOTA0-Tyr3]octreotate (7.4 GBq × 4 cycles) | Octreotide LAR, 60 mg/mo | NR vs. 8 | 0.21 (0.13–0.34) |
↵* With continuation of somatostatin analog therapy.
PFS = progression-free survival (intervention vs. control); HR = hazard ratio for disease progression and (disease-related) death; LAR = long-acting and repeatable; NR = not reached.